Related Experiment Videos
[Kaposi's sarcoma complicating long-term corticotherapy for severe asthma]
La Revue De Medecine Interne
|July 1, 1990
Summary
Long-term corticosteroid use, like prednisone for asthma, can trigger Kaposi's sarcoma in immunocompromised patients. Discontinuing these drugs may lead to remission of the skin lesions.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Kaposi's sarcoma (KS) is an opportunistic malignancy often associated with immune deficiency.
- Drug-induced immunosuppression, particularly from corticosteroids, is a recognized risk factor for KS development.
- Patients with pre-existing immune deficiencies, viral infections (like HHV-8), or genetic predispositions are more susceptible.
Observation:
- A case report details a 75-year-old male patient with severe asthma on continuous oral prednisone for 7 years.
- This patient developed Kaposi's sarcoma.
- The prolonged corticosteroid therapy likely contributed to his immunosuppression, creating a favorable environment for KS.
Findings:
- Corticosteroid therapy can act as a trigger for Kaposi's sarcoma in susceptible individuals.
- The development of KS in this case was linked to iatrogenic immunosuppression.
- Literature supports the role of corticosteroids in precipitating KS, especially when other risk factors are present.
Implications:
- Clinicians should consider KS in immunocompromised patients on long-term corticosteroids presenting with characteristic lesions.
- Discontinuation of corticosteroid therapy may be a viable treatment strategy, potentially leading to KS remission.
- This case highlights the importance of monitoring for opportunistic infections and malignancies in patients undergoing immunosuppressive therapy.